Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
American Institute of Research
1961
mi
from 43215
Whittier, CA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
American Institute of Research
1961
mi
from 43215
Whittier, CA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Yale Cancer Center
537
mi
from 43215
New Haven, CT
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Yale Cancer Center
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Florida Cancer Specialists
925
mi
from 43215
Fort Myers, FL
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Florida Cancer Specialists
925
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Florida Cancer Specialists and Research Institute
842
mi
from 43215
Saint Petersburg, FL
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Florida Cancer Specialists and Research Institute
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Central Indiana Cancer Centers
165
mi
from 43215
Carmel, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Central Indiana Cancer Centers
165
mi
from 43215
Carmel, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Indiana University
167
mi
from 43215
Indianapolis, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Indiana University
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Indiana University Health Ball Memorial Hospital
125
mi
from 43215
Muncie, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Indiana University Health Ball Memorial Hospital
125
mi
from 43215
Muncie, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Community Hospital
258
mi
from 43215
Munster, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Community Hospital
258
mi
from 43215
Munster, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Floyd Memorial Cancer Center of Indiana
188
mi
from 43215
New Albany, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Floyd Memorial Cancer Center of Indiana
188
mi
from 43215
New Albany, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Owsley Brown Frazier Cancer Center-Louisville Downtown
188
mi
from 43215
Louisville, KY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Owsley Brown Frazier Cancer Center-Louisville Downtown
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Tulane University
797
mi
from 43215
New Orleans, LA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Tulane University
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Ann Arbor Hematology Oncology Associates
167
mi
from 43215
Ann Arbor, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Ann Arbor Hematology Oncology Associates
167
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Barbara Ann Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Barbara Ann Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Sparrow Regional Cancer Center
206
mi
from 43215
Lansing, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Sparrow Regional Cancer Center
206
mi
from 43215
Lansing, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Metro Health Cancer Center
246
mi
from 43215
Wyoming, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Metro Health Cancer Center
246
mi
from 43215
Wyoming, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Southeast Nebraska Cancer Center
719
mi
from 43215
Lincoln, NE
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Southeast Nebraska Cancer Center
719
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Broome Oncology, LLC
396
mi
from 43215
Johnson City, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Broome Oncology, LLC
396
mi
from 43215
Johnson City, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Memorial Sloan-Kettering Cancer Center
480
mi
from 43215
New York, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Memorial Sloan-Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
University of Rochester
354
mi
from 43215
Rochester, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
University of Rochester
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Blumenthal Cancer Center
349
mi
from 43215
Charlotte, NC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Blumenthal Cancer Center
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Piedmont Hematology-Oncology Associates
307
mi
from 43215
Winston-Salem, NC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Piedmont Hematology-Oncology Associates
307
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Oncology Hematology Care
86
mi
from 43215
Cincinnati, OH
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Oncology Hematology Care
86
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Signal Point Clinical Research Center, LLC
78
mi
from 43215
Middletown, OH
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Signal Point Clinical Research Center, LLC
78
mi
from 43215
Middletown, OH
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Willamette Valley Cancer Institute/Research Ctr
2055
mi
from 43215
Eugene, OR
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Willamette Valley Cancer Institute/Research Ctr
2055
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Providence Portland Medical Center
2026
mi
from 43215
Portland, OR
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Providence Portland Medical Center
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Charleston Hematology Oncology Associates, PA
520
mi
from 43215
Charleston, SC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Charleston Hematology Oncology Associates, PA
520
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Cancer Centers of the Carolinas - Grove Commons
358
mi
from 43215
Greenville, SC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Cancer Centers of the Carolinas - Grove Commons
358
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Chattanooga Oncology Hematology Associates
362
mi
from 43215
Chattanooga, TN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Chattanooga Oncology Hematology Associates
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology - Arlington South
928
mi
from 43215
Arlington, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology - Arlington South
928
mi
from 43215
Arlington, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
909
mi
from 43215
Dallas, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
909
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology-Tyler
862
mi
from 43215
Tyler, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology-Tyler
862
mi
from 43215
Tyler, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
University of Utah Hospital and Clinics
1511
mi
from 43215
Salt Lake City, UT
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
University of Utah Hospital and Clinics
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Virginia Cancer Institute
338
mi
from 43215
Richmond, VA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Virginia Cancer Institute
338
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Puget Sound Cancer Centers
2007
mi
from 43215
Edmonds, WA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Puget Sound Cancer Centers
2007
mi
from 43215
Edmonds, WA
Click here to add this to my saved trials
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated:  7/24/2012
The Miriam Hospital
619
mi
from 43215
Providence, RI
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated: 7/24/2012
The Miriam Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/24/2012
LSU Health Sciences Center, 1501 Kings Highway
787
mi
from 43215
Shreveport, LA
Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/24/2012
LSU Health Sciences Center, 1501 Kings Highway
787
mi
from 43215
Shreveport, LA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Eastern Regional Medical Center
419
mi
from 43215
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Eastern Regional Medical Center
419
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
University of California, Irvine
1958
mi
from 43215
Irvine, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
University of California, Irvine
1958
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
UMDNJ
468
mi
from 43215
Newark, NJ
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
UMDNJ
468
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Beth Israel Med Ctr
478
mi
from 43215
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Beth Israel Med Ctr
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Mount Sinai School of Medicine
481
mi
from 43215
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Mount Sinai School of Medicine
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Home Telemonitoring for Patients With Lung Cancer
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca
Status: Enrolling
Updated:  8/21/2012
WVU Mary Babb Randolph Cancer Center and Ruby Hospital
164
mi
from 43215
Morgantown, WV
Home Telemonitoring for Patients With Lung Cancer
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca
Status: Enrolling
Updated: 8/21/2012
WVU Mary Babb Randolph Cancer Center and Ruby Hospital
164
mi
from 43215
Morgantown, WV
Click here to add this to my saved trials
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  8/24/2012
University of Kansas Medical Centner
627
mi
from 43215
Kansas City, KA
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 8/24/2012
University of Kansas Medical Centner
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  8/24/2012
University of Nebraska & Omaha VA
682
mi
from 43215
Omaha, NE
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 8/24/2012
University of Nebraska & Omaha VA
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Marin Specialty Care
2109
mi
from 43215
Greenbrae, CA
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Marin Specialty Care
2109
mi
from 43215
Greenbrae, CA
Click here to add this to my saved trials